Treatment for Peanut Allergies (Peanut [Arachis hypogaea] allergen powder-dnfp / Palforzia)
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy defines Blue Cross Blue Shield - Rhode Island coverage stance for peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia) for members and Medicare Advantage enrollees, summarizing evidence, regulatory status, and billing guidance.
No material clinical or coverage changes in this revision.
Coverage Determinations
Coverage determinations
Coverage stance by product type
For Medicare Advantage enrollees, the use of peanut (Arachis hypogaea) allergen powder-dnfp is not covered. The policy determination is based on the finding that current evidence is insufficient to determine effects on health outcomes for this technology.
For Commercial products, the use of peanut (Arachis hypogaea) allergen powder-dnfp is considered not medically necessary. This designation reflects the conclusion that the evidence is insufficient to determine effects on health outcomes for this therapy.
This medical policy is provided for informational purposes and is not a guarantee of payment. Coverage and eligibility are governed by the member’s subscriber agreement, member certificate, and/or employer agreement, which supersede this policy. Providers should verify member-specific benefits via the provider call center and consult applicable participation agreements for billing and collection rules. If services are determined to be not medically necessary or are non-covered benefits, providers may not charge the member unless the member has been informed and has provided prior written agreement to accept financial responsibility.
Use of this therapy for members under Commercial coverage is classified as not medically necessary because the available evidence does not adequately demonstrate a beneficial effect on health outcomes. Providers should document clinical rationale if considering off-label or investigational use and confirm member benefits before initiating treatment.
Billing and Coding Guidance
| J8499 | Prescription drug, oral, non-chemotherapeutic, NOS |
| No codes listed |
Provider Responsibilities and Billing Actions
Prior authorization — confirm with member documents
Prior authorization is listed as not applicable in this policy; however benefits may vary by contract so confirm any applicable prior authorization requirements in the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement.
Check member-specific prior authorization and eligibility
Benefits and eligibility are governed by the member's subscriber agreement or employer agreement; contact the provider call center for member-specific prior authorization or eligibility questions before providing services.
Verify contract-level step therapy and coverage rules
Benefits and coverage may vary between groups and contracts; refer to the appropriate Benefit Booklet, Evidence of Coverage, Subscriber Agreement, or employer documents for any step‑therapy or contract‑level requirements.
Billing and documentation requirements — verify, document, and retain records
Providers must maintain documentation of benefit verification, member notification, and any prior written member agreement to pay for non‑covered services; file claims with J8499 and retain supporting medical records per payer requirements.
- Document verification via provider call center and retain call/confirmation details.
- Keep written member consent if member agrees to self‑pay for non‑covered services.
- Include clinical records showing medical necessity rationale when submitting claims.
Verify member benefits and eligibility before services
Confirm member benefits and eligibility via the provider call center and review the member's subscriber agreement or employer agreement to determine whether the service is a covered benefit before scheduling or billing.
Coverage‑based denial risk — not covered / not medically necessary
Use of peanut (Arachis hypogaea) allergen powder‑dnfp is considered not covered for Medicare Advantage and not medically necessary for Commercial products; submitting claims without confirmed coverage risks denial.
Member financial responsibility when services are non‑covered
If services are determined to be not medically necessary or are non‑covered benefits, the provider may not charge the member unless the member has been informed and has provided prior written agreement to pay; check participation agreements for applicable provisions.
- Do not charge members for non‑covered or not medically necessary services unless there is prior written member agreement.
- Refer to your participation agreement(s) for billing provisions.
Clinical Background
Peanut allergy is the most common food allergy in U.S. children and often persists into adulthood. Diagnosis typically relies on a compatible clinical history together with testing such as skin prick testing and specific IgE; the double-blind, placebo-controlled oral food challenge remains the diagnostic gold standard but carries significant risk. Standard management emphasizes strict avoidance of peanut and prompt treatment of allergic reactions; oral immunotherapy approaches, including peanut allergen powders, have been studied but their clinical benefits and risks remain under evaluation.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.